Article Details

Seaport Therapeutics closes $225 million Series B to develop neuropsychiatric drugs

Retrieved on: 2024-10-22 14:04:35

Tags for this article:

Click the tags to see associated articles and topics

Seaport Therapeutics closes $225 million Series B to develop neuropsychiatric drugs. View article details on hiswai:

Excerpt

The original investors in Seaport also contributed to the Series B including ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and co ...

Article found on: www.outsourcing-pharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up